X4 Pharma shareholders approve 1.5M share equity plan increase, elect three directors at 2026 annual meeting

X4 Pharmaceuticals, Inc

• Shareholders approved 1,500,000 additional shares under Second Amended and Restated 2017 Equity Incentive Plan.
• Elected Gary Bridger, Françoise De Craecker, and Michael Wyzga as Class III directors until 2029.
• Ratified PricewaterhouseCoopers as independent auditor for fiscal year ending Dec 31, 2026.
• Say-on-pay advisory vote passed with 70.9 million for, 5.4 million against (excluding broker non-votes).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.